Acticor Biotech SAS ALACT.PA Stock
Acticor Biotech SAS Price Chart
Acticor Biotech SAS ALACT.PA Financial and Trading Overview
| Acticor Biotech SAS stock price | 3.63 EUR |
| Previous Close | 5.1 EUR |
| Open | 5.12 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 5.1 - 5.14 EUR |
| 52 Week Range | 5 - 11 EUR |
| Volume | 401 EUR |
| Avg. Volume | 2.13K EUR |
| Market Cap | 64.14M EUR |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.67 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.5 EUR |
ALACT.PA Valuation Measures
| Enterprise Value | 61.29M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -4.064 |
Trading Information
Acticor Biotech SAS Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -24.55% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 11 EUR |
| 52 Week Low | 5 EUR |
| 50-Day Moving Average | 5.82 EUR |
| 200-Day Moving Average | 6.63 EUR |
ALACT.PA Share Statistics
| Avg. Volume (3 month) | 2.13K EUR |
| Avg. Daily Volume (10-Days) | 2.05K EUR |
| Shares Outstanding | 12.3M |
| Float | 3.51M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 0% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -61.31% |
| Return on Equity (ttm) | -361.89% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -15080000 EUR |
| Net Income Avi to Common (ttm) | -15878000 EUR |
| Diluted EPS (ttm) | -1.48 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.6M EUR |
| Total Cash Per Share (mrq) | 0.63 EUR |
| Total Debt (mrq) | 9.23M EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.752 |
| Book Value Per Share (mrq) | -0.213 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -12104000 EUR |
| Levered Free Cash Flow (ttm) | -5808625 EUR |
Profile of Acticor Biotech SAS
| Country | France |
| State | N/A |
| City | Paris |
| Address | Hôpital Bichat |
| ZIP | 75018 |
| Phone | 33 6 76 23 38 13 |
| Website | https://www.acticor-biotech.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 29 |
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19). The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks. The company was incorporated in 2013 and is headquartered in Paris, France.
Q&A For Acticor Biotech SAS Stock
What is a current ALACT.PA stock price?
Acticor Biotech SAS ALACT.PA stock price today per share is 3.63 EUR.
How to purchase Acticor Biotech SAS stock?
You can buy ALACT.PA shares on the Paris exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Acticor Biotech SAS?
The stock symbol or ticker of Acticor Biotech SAS is ALACT.PA.
Which industry does the Acticor Biotech SAS company belong to?
The Acticor Biotech SAS industry is Biotechnology.
How many shares does Acticor Biotech SAS have in circulation?
The max supply of Acticor Biotech SAS shares is 15.69M.
What is Acticor Biotech SAS Price to Earnings Ratio (PE Ratio)?
Acticor Biotech SAS PE Ratio is now.
What was Acticor Biotech SAS earnings per share over the trailing 12 months (TTM)?
Acticor Biotech SAS EPS is -1.67 EUR over the trailing 12 months.
Which sector does the Acticor Biotech SAS company belong to?
The Acticor Biotech SAS sector is Healthcare.